The Zivin et al. study has other methodological problems. The authors collapsed categories of a comorbidity index into one continuous covariate, altering magnitudes of comorbidity and increasing the possibility of data misinterpretation (3). Their study does not address whether particularly elevated risk exists in individuals with specific comorbid illnesses (e.g., heart failure)—those individuals targeted in the FDA warning. In addition, the person-time measure used by the authors permits more than one observation for the same individual during periods when different dosages were prescribed. In this situation, the possible group effects generated between different individuals and within the same individual in regression analyses should be examined; otherwise, the precision of regression estimates is compromised. Finally, contrary to the FDA warning, the authors concluded that no increase in risk of ventricular arrhythmia was associated with high-dosage citalopram treatment without providing the theoretical explanation for their finding. Their results suggested that high-dosage antidepressants decreased the risk, although they avoided coming to that conclusion. Further study is needed to unravel the biological mechanisms underlying that finding.

Second-generation antipsychotics have largely supplanted their first-generation counterparts in the last decade, and studies have attempted to derive chlorpromazine equivalents for these agents either through expert consensus or calculation methods. This calls into question the impact of these different approaches on studies employing chlorpromazine equivalents.

The estimated doses of five commonly prescribed second-generation antipsychotics, using four widely used methods, are listed in Table 1. Immediately apparent is the wide variation in calculated doses for any given second-generation antipsychotics; for example, at 600 mg of chlorpromazine equivalents, doses of risperidone vary between 6 mg and 12 mg and doses of aripiprazole vary between 24 mg and 45 mg. These differences are amplified at 1,000 mg of chlorpromazine equivalents.

At 1,000 mg of chlorpromazine equivalents, calculated doses for the second-generation antipsychotics uniformly exceed the maximum dosages currently recommended for these agents (3). Even at 600 mg of chlorpromazine equivalents, values frequently lie outside the recommended dosage range. As importantly, the calculated doses differ markedly based on the method employed.

This variance raises practical considerations, for example, in declaring a failed second-generation antipsychotics trial in the process of defining treatment-resistant schizophrenia. The wide variation challenges the validity of using chlorpromazine equivalents to compare across antipsychotics. The reported near-maximal effective dose of chlorpromazine was 400–450 mg, not 600–1,000 mg, and there appears to be little evidence to support high doses in treatment-resistant schizophrenia (4). In addition, the high doses calculated raise serious safety concerns and fly in the face of regulatory dosing recommendations. Accordingly, adopting chlorpromazine equivalents may not be appropriate for evaluating an adequate dosage for specific second-generation antipsychotics, and we suggest that a more appropriate means to confirm a failed clinical trial is suboptimal response at the maximum recommended dosage range for a specific second-generation antipsychotics, as per product monograph.

References

SHUAI-TING LIN, M.D.
CHENG-CHUNG CHEN, M.D., Ph.D.
HIN-YEUNG TSANG, M.R.C.PSYCH., Ph.D.

From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan.

The authors report no financial relationships with commercial interests.

This letter (doi: 10.1176/appi.ajp.2013.13050632) was accepted for publication in July 2013.

The author reply is contained within the Commentary on pp 20–22, “Safety of High-Dosage Citalopram.”

Adequate Dosing for Second-Generation Antipsychotics in Establishing Treatment Resistance in Schizophrenia

To the Editor: Treatment resistance in schizophrenia requires evidence of two previous failed antipsychotic trials of 6 weeks at a dose of 600 mg in chlorpromazine equivalents (1), while the original criteria for clozapine’s role in treatment resistance stipulated a dose of 1,000 mg in chlorpromazine equivalents (2).
TABLE 1. Computed Doses of Antipsychotics at 600 and 1,000 mg Chlorpromazine Equivalents From Consensus and Calculation Methods

<table>
<thead>
<tr>
<th>Drug (mg)</th>
<th>600 mg Chlorpromazine Equivalents</th>
<th>1,000 mg Chlorpromazine Equivalents</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Consensus Calculation</td>
<td>Consensus Calculation</td>
<td>Highest Dose</td>
</tr>
<tr>
<td></td>
<td>Kaneb Gardnerc</td>
<td>Woodsd Andreasone</td>
<td>Kaneb Gardnerc</td>
</tr>
<tr>
<td>Risperidone</td>
<td>6.6 6 12 7.9</td>
<td>11.7 10.0 20.0 13.2</td>
<td>10.5 8.5 (1.0)</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>24.0 20 30 28.5</td>
<td>33.3 33.3 50.1 47.5</td>
<td>40.0 30 (0)</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>720.0 750 450 852.0</td>
<td>1,000.0 1,250.0 751.5 1,420.0</td>
<td>950.0 1,000 (162)</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>168.0 160 360 303.0</td>
<td>200.0 266.7 601.2 505.0</td>
<td>180.0 200 (40)</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>24.0 30 45 38.5</td>
<td>33.3 50 75.2 64.2</td>
<td>30.0 30 (0)</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>12.0 10 12 11.0</td>
<td>22.2 16.7 20.0 18.4</td>
<td>25.0 20 (4.0)</td>
</tr>
</tbody>
</table>

a Recommended dose range for treatment of an acute episode (3).
b Doses obtained and approximated from haloperidol, 10 mg for 600 mg of chlorpromazine equivalents and 20 mg for 1,000 mg of chlorpromazine equivalents, from guideline 5A of Kane et al. (4).
c Doses computed from dose equivalency ratio versus chlorpromazine (5).
d Doses calculated from table provided in Woods (6).
e Doses calculated from power transformation for chlorpromazine equivalent (7).
f Median (interquartile range) maximum doses (5).


JIMMY LEE, M.B.B.S., M.MSc.
GARY REMINGTON, M.D., Ph.D.

From the Department of General Psychiatry I and Research Division, Institute of Mental Health, Singapore; the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto; and the Department of Psychiatry, University of Toronto.

Dr. Lee has served as a consultant for Roche and is currently supported by the Singapore Ministry of Health’s National Medical Research Council under its Transition Award (grant NMRC/TA/002/2012). Dr. Remington has received research support, consulting fees, or speaker’s fees from the Canadian Diabetes Association, the Canadian Institutes of Health Research, Hoffman-La Roche, Laboratorios Farmacéuticos Rovi, Medicare, Neurocience Biosciences, Novartis Canada, Research Hospital Fund–Canada Foundation for Innovation, and the Schizophrenia Society of Ontario.

This letter (doi: 10.1176/appi.ajp.2013.13070965) was accepted for publication in November 2013.

Metformin and Alzheimer’s Disease Risk

To the Editor: In the September issue of the Journal, Jarskog et al. (1) report and Correll et al. (2) discuss a 4-month trial of metformin that concluded “metformin was modestly effective in reducing … risk factors for cardiovascular disease” and “represents a safe … option for patients who are motivated to lose weight.” That study spanned 4 months, but the treatment of cardiovascular risk factors may continue indefinitely. Imfeld et al. (3) reported that long-term metformin use (over 60 prescriptions or more than 7 years) but not use of other antidiabetic medications such as sulfonylureas, thiazolidinediones, or insulin was associated with a small increased risk of developing Alzheimer’s disease (adjusted odds ratio, 1.71).

I would be grateful if Jarskog et al. and Correll et al. would compare the benefit they anticipate from reducing cardiovascular risk factors with metformin in psychiatric, non-diabetic patients to the risk of increased Alzheimer’s disease from metformin.

References

JONATHAN E. ROSENFELD, M.D., Ph.D.

From the Department of Psychiatry, St. Luke’s-Roosevelt Hospital Center, and the Department of Psychiatry, Columbia University, New York.

The author reports no financial relationships with commercial interests.

This letter (doi: 10.1176/appi.ajp.2013.13091193) was accepted for publication in October 2013.

Response to Rosenfeld

To the Editor: We appreciate Dr. Rosenfeld bringing attention to a recent report by Imfeld et al. (1) suggesting that long-term metformin use may increase the risk for Alzheimer’s disease in elderly patients with diabetes mellitus. In fact, a number of clinical and preclinical reports within the past 5...